FR18C1031I1 - - Google Patents
Info
- Publication number
- FR18C1031I1 FR18C1031I1 FR18C1031C FR18C1031I1 FR 18C1031 I1 FR18C1031 I1 FR 18C1031I1 FR 18C1031 C FR18C1031 C FR 18C1031C FR 18C1031 I1 FR18C1031 I1 FR 18C1031I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010257022 | 2010-11-17 | ||
| PCT/JP2011/076486 WO2012067176A1 (en) | 2010-11-17 | 2011-11-17 | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR18C1031I1 true FR18C1031I1 (en) | 2018-08-31 |
| FR18C1031I2 FR18C1031I2 (en) | 2020-09-25 |
Family
ID=46084097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR18C1031C Active FR18C1031I2 (en) | 2010-11-17 | 2018-07-19 | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH AN ALTERNATIVE FUNCTION TO THE BLOOD COAGULATION FACTOR VIII FUNCTION |
Country Status (29)
| Country | Link |
|---|---|
| US (9) | US9334331B2 (en) |
| EP (2) | EP2644698B1 (en) |
| JP (7) | JP6013915B2 (en) |
| KR (4) | KR101962483B1 (en) |
| CN (2) | CN105859889B (en) |
| AU (2) | AU2011330184B2 (en) |
| BR (1) | BR112013012213A2 (en) |
| CA (1) | CA2817964C (en) |
| DK (1) | DK2644698T3 (en) |
| ES (1) | ES2660151T3 (en) |
| FR (1) | FR18C1031I2 (en) |
| HK (1) | HK1223379A1 (en) |
| HR (1) | HRP20180421T1 (en) |
| HU (2) | HUE038305T2 (en) |
| LT (2) | LT2644698T (en) |
| LU (1) | LUC00076I2 (en) |
| MX (1) | MX355060B (en) |
| MY (1) | MY166429A (en) |
| NL (1) | NL300940I2 (en) |
| NO (2) | NO2644698T3 (en) |
| PH (1) | PH12016502073A1 (en) |
| PL (1) | PL2644698T3 (en) |
| PT (1) | PT2644698T (en) |
| RS (1) | RS57038B1 (en) |
| RU (3) | RU2620071C2 (en) |
| SI (1) | SI2644698T1 (en) |
| TR (1) | TR201802772T4 (en) |
| TW (4) | TWI629355B (en) |
| WO (1) | WO2012067176A1 (en) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL217296B1 (en) * | 2002-11-15 | 2014-07-31 | Genmab As | Human monoclonal antibodies against cd25 |
| WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| US8178099B2 (en) | 2006-12-29 | 2012-05-15 | Osteogenex Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| JP5564266B2 (en) * | 2007-02-16 | 2014-07-30 | メリマック ファーマシューティカルズ インコーポレーティッド | Antibodies against ERBB3 and uses thereof |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| SG10201605394SA (en) | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
| EP2409990A4 (en) | 2009-03-19 | 2013-01-23 | Chugai Pharmaceutical Co Ltd | Antibody constant region variant |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| CA2785414C (en) * | 2009-12-25 | 2019-01-22 | Tomoyuki Igawa | Polypeptide modification method for purifying polypeptide multimers |
| TWI609698B (en) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody-containing solution preparation |
| JP5889181B2 (en) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | Antibody constant region variants |
| AU2011250920B2 (en) * | 2010-05-14 | 2015-05-21 | Amgen Inc. | High concentration antibody formulations |
| KR101962483B1 (en) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor VIII |
| LT2647707T (en) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| KR102168733B1 (en) | 2011-10-31 | 2020-10-23 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
| WO2013170168A1 (en) | 2012-05-10 | 2013-11-14 | Bioatla Llc | Multi-specific monoclonal antibodies |
| SG11201502279YA (en) * | 2012-09-26 | 2015-04-29 | Julius Maximilians Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| PL2902787T3 (en) | 2012-09-28 | 2018-08-31 | Chugai Seiyaku Kabushiki Kaisha | Method for evaluating blood coagulation reaction |
| WO2015013671A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| BR112016006197B1 (en) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY |
| US9944697B2 (en) * | 2013-11-06 | 2018-04-17 | Jansson Biotech, Inc. | Anti-CCL17 antibodies |
| US11072647B2 (en) * | 2013-12-19 | 2021-07-27 | Onsejo Nacional DE Investigation Cientiticay Tecnica | TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro |
| EP3089994B1 (en) * | 2013-12-30 | 2022-05-04 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EP3102939A4 (en) * | 2014-02-05 | 2018-02-28 | Dana-Farber Cancer Institute, Inc. | AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF |
| US20170204174A1 (en) * | 2014-03-26 | 2017-07-20 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
| CN105294857B (en) * | 2014-06-18 | 2019-02-19 | 上海交通大学 | FIX-based epitope and application thereof |
| WO2015196142A1 (en) * | 2014-06-20 | 2015-12-23 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| TW201625299A (en) * | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| WO2016009017A1 (en) * | 2014-07-16 | 2016-01-21 | Institut Gustave-Roussy | Combination of oncolytic virus with immune checkpoint modulators |
| JP6858559B2 (en) | 2014-08-20 | 2021-04-14 | 中外製薬株式会社 | Method for measuring viscosity of protein solution |
| TWI701435B (en) * | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | Method to determine the reactivity of FVIII |
| TWI700300B (en) * | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII) |
| CA2967222C (en) * | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| JPWO2016104657A1 (en) * | 2014-12-26 | 2017-10-12 | 株式会社セラバイオファーマ | Cancer treatment |
| JP6763783B2 (en) | 2015-01-30 | 2020-09-30 | 学校法人 埼玉医科大学 | Anti-ALK2 antibody |
| KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
| JP2018508509A (en) * | 2015-02-22 | 2018-03-29 | ソレント・セラピューティクス・インコーポレイテッド | Antibody drugs that bind to CD137 |
| WO2016156440A1 (en) * | 2015-03-31 | 2016-10-06 | Medimmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| WO2016159213A1 (en) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | Method for producing polypeptide hetero-oligomer |
| MX2017010734A (en) | 2015-04-17 | 2017-12-04 | Hoffmann La Roche | Combination therapy with coagulation factors and multispecific antibodies. |
| CN107533071A (en) * | 2015-04-24 | 2018-01-02 | 公立大学法人奈良县立医科大学 | The evaluation method of the coagulation ability of blood subject and reagent, kit and device for using in the method |
| JP2018123055A (en) * | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | Pharmaceutical composition for use in prevention and/or treatment of blood coagulation factor xi (fxi) abnormalities comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii (fviii) |
| JP2018516248A (en) | 2015-05-29 | 2018-06-21 | アンフィヴェナ セラピューティクス，インク． | Methods of using bispecific CD33 and CD3 binding proteins |
| JP6823596B2 (en) | 2015-07-31 | 2021-02-03 | 中外製薬株式会社 | Method for Purifying Composition Containing Antibody with Anionic Polymer |
| CN108271372B (en) | 2015-09-18 | 2021-07-09 | 中外制药株式会社 | IL-8-binding antibodies and uses thereof |
| MX2018005720A (en) * | 2015-11-17 | 2018-11-09 | Suzhou Suncadia Biopharmaceuticals Co Ltd | Pd-l1 antibody, antigen fragment binding thereof and pharmaceutical use thereof. |
| JP6954842B2 (en) * | 2015-12-25 | 2021-10-27 | 中外製薬株式会社 | Antibodies with enhanced activity and methods for modifying them |
| AU2016381992B2 (en) * | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| CA3011092A1 (en) * | 2016-01-12 | 2017-07-20 | Palleon Pharmaceuticals Inc. | Use of siglec-7 or siglec-9 antibodies for the treatment of cancer |
| TW202402326A (en) | 2016-04-28 | 2024-01-16 | 日商中外製藥股份有限公司 | Antibody-containing preparation |
| CN113372446A (en) * | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | Antibodies for binding interleukin-4 receptor |
| KR102492057B1 (en) * | 2016-06-15 | 2023-01-26 | 노파르티스 아게 | Methods of treating diseases using inhibitors of bone morphogenetic protein 6 (BMP6) |
| PE20190418A1 (en) * | 2016-07-14 | 2019-03-19 | Bristol Myers Squibb Co | ANTIBODIES AGAINST PROTEIN 3 CONTAINING THE MUCIN AND IMMUNOGLOBULIN T-LYMPHOCYTE DOMAIN (TIM3) AND THEIR USES |
| WO2018021450A1 (en) | 2016-07-29 | 2018-02-01 | 中外製薬株式会社 | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| CA3035202A1 (en) | 2016-09-01 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| IL265144B1 (en) | 2016-09-06 | 2024-06-01 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| JP7069177B2 (en) * | 2016-09-21 | 2022-05-17 | ネクストキュア インコーポレイテッド | Antibodies to Siglec-15 and how to use them |
| JP7051826B2 (en) * | 2016-09-23 | 2022-04-11 | シーエスエル、リミテッド | Coagulation factor binding protein and its use |
| EA201991075A1 (en) | 2016-11-08 | 2019-10-31 | ANTIGEN-BINDING PROTEINS THAT MANIFESTATE ANTAGONISM WITH RESPECT TO THE LEPTIN RECEPTOR | |
| BR112019010349A2 (en) * | 2016-11-23 | 2019-10-08 | Bioverativ Therapeutics Inc | ANTI-FIXED ANTIBODIES, ANTI-FXZ AND ANTIFXA, BIESPECIFIC MOLECULE, NULCEIC ACID, PHARMACEUTICAL COMPOSITION AND USE OF PREVIOUS |
| BR112019012731A2 (en) * | 2016-12-21 | 2019-11-26 | Mereo Biopharma 3 Ltd | use of antisclerostin antibodies in the treatment of osteogenesis imperfecta |
| EP3574017A1 (en) * | 2017-01-27 | 2019-12-04 | Kymab Limited | Anti-opg antibodies |
| EP3848396A1 (en) * | 2017-02-01 | 2021-07-14 | Novo Nordisk A/S | Antibodies recognising factor ix and x for use in promoting coagulation |
| EP3582813A4 (en) * | 2017-02-16 | 2020-12-30 | XBiotech, Inc | Treatment of hidradenitis suppurativa |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| TW201836636A (en) | 2017-03-31 | 2018-10-16 | 公立大學法人奈良縣立醫科大學 | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
| AU2018246377A1 (en) * | 2017-03-31 | 2019-10-17 | Cellectis Sa | Universal anti-CD22 chimeric antigen receptor engineered immune cells |
| CA3058134A1 (en) * | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| PE20191844A1 (en) * | 2017-05-26 | 2019-12-31 | Glaxosmithkline Ip Dev Ltd | BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS |
| MX2019014375A (en) * | 2017-06-01 | 2020-01-23 | Jiangsu Hengrui Medicine Co | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof. |
| GB201709970D0 (en) * | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| TWI726228B (en) * | 2017-08-09 | 2021-05-01 | 國立臺灣大學 | Use of cd14 antagonists for treating cancer |
| CN111065649A (en) * | 2017-08-16 | 2020-04-24 | 蜻蜓疗法股份有限公司 | Proteins that bind NKG2D, CD16 and EGFR, HLA-E, CCR4 or PD-L1 |
| WO2019040674A1 (en) | 2017-08-22 | 2019-02-28 | Sanabio, Llc | Soluble interferon receptors and uses thereof |
| US11572409B2 (en) * | 2017-09-21 | 2023-02-07 | Imcheck Therapeutics Sas | Antibodies having specificity for BTN2 and uses thereof |
| PE20210005A1 (en) * | 2017-09-29 | 2021-01-05 | Chugai Pharmaceutical Co Ltd | MULTISPECIFIC ANTIGEN BINDING MOLECULA THAT HAS SUBSTITUTE ACTIVITY OF THE COFACTOR FUNCTION OF BLOOD COAGULATION FACTOR VIII (FVIII) AND PHARMACEUTICAL FORMULATION THAT CONTAINS SUCH MOLECULA AS ACTIVE INGREDIENT |
| RU2698048C2 (en) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | Monoclonal antibody to il-5rα |
| CA3079053A1 (en) | 2017-11-01 | 2019-05-09 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
| EP3710486A1 (en) | 2017-11-15 | 2020-09-23 | Novo Nordisk A/S | Factor x binders enhancing fx activation |
| WO2019104157A1 (en) * | 2017-11-21 | 2019-05-31 | The University Of Vermont And State Agricultural College | Highly specific zika neutralizing human antibodies |
| MA51289A (en) | 2017-12-18 | 2021-03-24 | Regeneron Pharma | BISPECIFIC ANTIGEN BINDING MOLECULES BINDING TO THE LEPTIN RECEPTOR AND / OR GP130, AND THEIR METHODS OF USE |
| CN109957026A (en) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | Covalent multi-specificity antibody |
| EP3749346B1 (en) | 2018-02-08 | 2024-07-10 | Dragonfly Therapeutics, Inc. | Antibody variable domain combinations targeting the nkg2d receptor |
| WO2019155427A1 (en) * | 2018-02-09 | 2019-08-15 | Nestlé Skin Health Sa | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation |
| WO2019177138A1 (en) * | 2018-03-16 | 2019-09-19 | 国立大学法人滋賀医科大学 | Antibody fragment degrading and removing abnormal tdp-43 |
| EP3773713A1 (en) * | 2018-04-06 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
| JP7470987B2 (en) * | 2018-05-09 | 2024-04-19 | グッド ティー セルズ、 インコーポレイテッド | Epitopes on regulatory T cell surface antigens and antibodies that specifically bind thereto |
| JPWO2019225568A1 (en) | 2018-05-21 | 2021-07-01 | 中外製薬株式会社 | Lyophilized preparation enclosed in a glass container |
| US11708186B2 (en) | 2018-05-28 | 2023-07-25 | Chugai Seiyaku Kabushiki Kaisha | Filling nozzle |
| JP7370322B2 (en) | 2018-06-04 | 2023-10-27 | 中外製薬株式会社 | How to detect complexes |
| EP3806885A2 (en) * | 2018-06-13 | 2021-04-21 | Kymab Limited | Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone |
| FR3082427B1 (en) | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | COMBINATION OF FACTOR VII AND A BISPECIFIC ANTIBODY ANTI-FACTORS IX AND X |
| TWI822815B (en) * | 2018-07-14 | 2023-11-21 | 財團法人生物技術開發中心 | Anti- human pd-l1 antibodies and their uses |
| US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
| WO2020025672A1 (en) * | 2018-08-01 | 2020-02-06 | Novo Nordisk A/S | Improved procoagulant antibodies |
| KR20210049840A (en) * | 2018-08-20 | 2021-05-06 | 화이자 인코포레이티드 | Anti-GDF15 antibodies, compositions and methods of use |
| SG11202102882YA (en) * | 2018-09-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule comprising altered antibody variable region |
| AU2019347412A1 (en) * | 2018-09-28 | 2021-05-27 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules capable of binding CD3 and CD137 but not simultaneously |
| US20220267428A1 (en) * | 2018-10-10 | 2022-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS |
| PE20211295A1 (en) * | 2018-12-21 | 2021-07-20 | 23Andme Inc | ANTI IL-36 ANTIBODIES AND PROCEDURES FOR THE USE OF THESE |
| BR112021012065A2 (en) * | 2018-12-21 | 2021-12-07 | Kymab Ltd | Bispecific antibody that binds Fixa and Fx and catalyzes Fixa-mediated activation of Fx; method; anti-fixed antibody; anti-fx antibody; isolated nucleic acid; in vitro host cell; in vitro host cell population; kit for producing a bispecific antibody; method of producing a bispecific antibody; composition; method for controlling bleeding in a patient with hemophilia a; use of a bispecific antibody; method, composition for use or use; and method for reducing the development of inhibitory anti-drug antibodies in a patient with hemophilia a undergoing treatment with a polypeptide that replaces the activity of fviiia |
| US20220082573A1 (en) * | 2018-12-29 | 2022-03-17 | Berysol Gmbh | Selenium binding protein 1 detection from body fluids for diagnosis of peracute tissue damage |
| JP2022526738A (en) * | 2019-03-21 | 2022-05-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | A combination of IL-4 / IL-13 pathway inhibitors and plasma cell removal to treat allergies |
| SG11202110626SA (en) * | 2019-03-27 | 2021-10-28 | Umc Utrecht Holding Bv | Engineered iga antibodies and methods of use |
| AU2020259982A1 (en) * | 2019-04-17 | 2021-10-28 | Novo Nordisk A/S | Bispecific antibodies |
| AU2020268619A1 (en) * | 2019-05-03 | 2021-12-16 | National University Of Singapore | Treatment and prevention of metabolic diseases |
| JP7122354B2 (en) * | 2019-09-24 | 2022-08-19 | 財團法人工業技術研究院 | Anti-TIGIT antibody and method of use |
| JP6836696B1 (en) | 2019-10-11 | 2021-03-03 | 中外製薬株式会社 | A pharmaceutical composition used for the prevention and / or treatment of acquired hemophilia A, and a product containing the pharmaceutical composition. |
| CA3150474A1 (en) | 2019-10-11 | 2021-04-15 | Geraint Iwan Davies | Drug dosage determination devices and methods |
| WO2021070885A1 (en) | 2019-10-11 | 2021-04-15 | 中外製薬株式会社 | Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition |
| US11890353B2 (en) * | 2019-10-15 | 2024-02-06 | Northwestern University | Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies |
| WO2021152066A1 (en) | 2020-01-30 | 2021-08-05 | Novo Nordisk A/S | Bispecific factor viii mimetic antibodies |
| CA3097453A1 (en) * | 2020-03-23 | 2021-09-23 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
| US11987640B2 (en) * | 2020-04-07 | 2024-05-21 | Fred Hutchinson Cancer Center | Anti-mesothelin antigen-binding molecules and uses thereof |
| JP2023106635A (en) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions |
| AU2021259628A1 (en) * | 2020-04-24 | 2023-01-05 | Millennium Pharmaceuticals, Inc. | Anti-CD19 antibodies and uses thereof |
| MX2022013310A (en) * | 2020-04-30 | 2022-11-14 | Genentech Inc | Kras specific antibodies and uses thereof. |
| IL298257A (en) * | 2020-05-22 | 2023-01-01 | Regeneron Pharma | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
| EP4155405A4 (en) | 2020-05-22 | 2024-07-03 | Chugai Pharmaceutical Co Ltd | Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity |
| BR112023001723A2 (en) | 2020-08-05 | 2023-05-02 | Synthekine Inc | GP130 BINDING MOLECULES AND METHODS OF USE |
| MX2023002106A (en) * | 2020-08-21 | 2023-03-15 | Genzyme Corp | Fgfr3 antibodies and methods of use. |
| WO2022094009A1 (en) * | 2020-10-30 | 2022-05-05 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Single domain antibodies to sars-cov-2 nucleocapsid protein |
| US20220144956A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII |
| US20220257614A1 (en) * | 2021-02-16 | 2022-08-18 | New York Medical College | Use of 12-lipoxygenase inhibitors in the treatment of covid-19 |
| JP2024512574A (en) * | 2021-03-22 | 2024-03-19 | ノビミューン エスアー | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof |
| WO2022204316A2 (en) * | 2021-03-24 | 2022-09-29 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
| JP2024518735A (en) * | 2021-04-23 | 2024-05-02 | アストラゼネカ・アクチエボラーグ | Treatment of lupus nephritis with the anti-type I IFN receptor antibody anifrolumab |
| AR127269A1 (en) | 2021-10-08 | 2024-01-03 | Chugai Pharmaceutical Co Ltd | ANTI-HLA-DQ2.5 ANTIBODY FORMULATION |
| KR20230130561A (en) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods of administering fviii mimetic bispecidic antibodies every second week |
| KR20230130560A (en) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods of administering fviii mimetic bispecidic antibodies once weekly |
| KR20230130558A (en) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Methods of administering fviii mimetic bispecidic antibodies once monthly |
| WO2024008904A2 (en) | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
Family Cites Families (233)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5824836B2 (en) | 1974-10-14 | 1983-05-24 | ノウミボウサイコウギヨウ カブシキガイシヤ | Kasainadonotsuhousouchi |
| JPS5334319A (en) | 1976-09-12 | 1978-03-30 | Nat Jutaku Kenzai | Entrance device of unit residence |
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| JPS59162441U (en) | 1983-04-14 | 1984-10-31 | 千代田紙業株式会社 | Heavy packaging with a blow-in port |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3583750D1 (en) | 1984-01-12 | 1991-09-19 | Chiron Corp | HYBRIDOME CELL LINES AND MONOCLONAL ANTIBODIES AGAINST FACTOR VIII-C. |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPH06104071B2 (en) | 1986-08-24 | 1994-12-21 | 財団法人化学及血清療法研究所 | Factor IX Monoclonal antibody specific for conformation |
| JPH0338228Y2 (en) | 1986-09-26 | 1991-08-13 | ||
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| IL89491A0 (en) | 1988-11-17 | 1989-09-10 | Hybritech Inc | Bifunctional chimeric antibodies |
| JPH0646389Y2 (en) | 1989-05-12 | 1994-11-30 | ナショナル住宅産業株式会社 | Handgrip mounting structure |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| KR100236375B1 (en) | 1989-12-11 | 1999-12-15 | 오트리브 데이비스 더블유 | Pharmaceutical compositions and kit for antibody targeting of diagnostic or therapeutic agents |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| TW212184B (en) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
| JPH05184383A (en) | 1990-06-19 | 1993-07-27 | Dainabotsuto Kk | Bispecific antibody |
| JPH05199894A (en) | 1990-08-20 | 1993-08-10 | Takeda Chem Ind Ltd | Bi-specific antibody and antibody-containing medicine |
| JP2938569B2 (en) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | Method for producing xenogeneic immunoglobulin and transgenic mouse |
| DE122009000019I1 (en) | 1991-04-25 | 2009-07-16 | Chugai Seiyaku K K 5 1 | RECOMBINED HUMAN ANTIBODIES AGAINST THE HUMAN INTERLEUKIN-6 RECEPTOR |
| JPH05304992A (en) | 1991-06-20 | 1993-11-19 | Takeda Chem Ind Ltd | Hybridoma-monoclonal antibody and medicine containing antibody |
| ATE297465T1 (en) | 1991-11-25 | 2005-06-15 | Enzon Inc | METHOD FOR PRODUCING MULTIVALENT ANTIGEN-BINDING PROTEINS |
| JPH07503132A (en) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | Transgenic non-human animals capable of producing xenoantibodies |
| JPH0767688B2 (en) | 1992-01-21 | 1995-07-26 | 近畿コンクリート工業株式会社 | PC concrete panel |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| JPH05203652A (en) | 1992-01-28 | 1993-08-10 | Fuji Photo Film Co Ltd | Antibody enzyme immunoassay |
| JPH05213775A (en) | 1992-02-05 | 1993-08-24 | Otsuka Pharmaceut Co Ltd | Bfa antibody |
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| WO1993017706A1 (en) | 1992-03-11 | 1993-09-16 | Agracetus, Inc. | Genetic vaccine for immunodeficiency viruses |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5744446A (en) | 1992-04-07 | 1998-04-28 | Emory University | Hybrid human/animal factor VIII |
| JPH07509137A (en) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | Production of xenoantibodies |
| ZA936260B (en) | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU7214294A (en) | 1993-07-01 | 1995-01-24 | Dade International Inc. | Process for the preparation of factor x depleted plasma |
| FR2707189B1 (en) | 1993-07-09 | 1995-10-13 | Gradient Ass | Method for treating combustion residues and installation for implementing said method. |
| UA40577C2 (en) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Bispecific antigen molecule for lysis of tumor cells, method for preparing of bispecific antigen molecule, monoclonal antibody (variants), pharmaceutical preparation, pharmaceutical kit for lysis of tumor cells (variants), method of lysis of tumor cells |
| IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| DE122009000068I2 (en) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Process for the preparation of heterologous bispecific antibodies |
| MX9700312A (en) | 1994-07-11 | 1997-07-31 | Univ Texas | Methods and compositions for the specific coagulation of vasculature. |
| WO1996002576A1 (en) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| RU2147443C1 (en) | 1994-10-07 | 2000-04-20 | Чугаи Сейяку Кабусики Кайся | Drugs against chronic rheumatic arthritis containing antagonist of il-6 as effective component |
| RU2147442C1 (en) | 1994-10-21 | 2000-04-20 | Кисимото Тадамицу | Pharmaceutical composition for prophylaxis or treatment of diseases caused by il-6 formation |
| WO1996016673A1 (en) | 1994-12-02 | 1996-06-06 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
| US6485943B2 (en) | 1995-01-17 | 2002-11-26 | The University Of Chicago | Method for altering antibody light chain interactions |
| AU4865296A (en) | 1995-02-28 | 1996-09-18 | Procter & Gamble Company, The | Preparation of noncarbonated beverage products having superior microbial stability |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6018032A (en) | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| MA24512A1 (en) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | PROCESS FOR THE PREPARATION OF ANTICOAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS |
| ZA976326B (en) | 1996-07-19 | 1998-02-03 | Amgen Inc | Analogs of cationic proteins. |
| JPH10165184A (en) | 1996-12-16 | 1998-06-23 | Tosoh Corp | Antibody, gene and production of chimera antibody |
| US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| ES2246069T3 (en) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS. |
| DE19725586C2 (en) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Process for the preparation of cell preparations for immunization by means of heterologous intact bispecific and / or trispecific antibodies |
| US5980893A (en) | 1997-07-17 | 1999-11-09 | Beth Israel Deaconess Medical Center, Inc. | Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis |
| US6207805B1 (en) | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO1999018212A1 (en) | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Natural human antibody |
| CN1073412C (en) | 1998-03-19 | 2001-10-24 | 中国科学院化学研究所 | Method for prepn. of macromolecule microcapsule |
| CN1303431A (en) | 1998-04-03 | 2001-07-11 | 中外制药株式会社 | Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody |
| DK1071700T3 (en) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity |
| DE19819846B4 (en) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalent antibody constructs |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| AU764211C (en) | 1998-12-01 | 2006-03-30 | Abbvie Biotherapeutics Inc. | Humanized antibodies to gamma-interferon |
| US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| ES2568898T3 (en) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of an immunofunctional molecule |
| EP1074842A1 (en) | 1999-07-21 | 2001-02-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Catalytic anti-factor VIII allo-antibodies |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| NL1012907C2 (en) * | 1999-08-25 | 2001-02-27 | Amb It Holding Bv | System for determining the position of a transponder. |
| AT411997B (en) * | 1999-09-14 | 2004-08-26 | Baxter Ag | FACTOR IX / FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES |
| SE9903895D0 (en) | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
| WO2001075454A2 (en) | 2000-04-03 | 2001-10-11 | Oxford Glycosciences (Uk) Ltd. | Diagnosis and treatment of alzheimer's disease |
| EP1278512A2 (en) | 2000-05-03 | 2003-01-29 | MBT Munich Biotechnology AG | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| WO2001090192A2 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| US7160540B2 (en) | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| EP1304573A4 (en) | 2000-07-17 | 2006-06-07 | Chugai Pharmaceutical Co Ltd | Method for screening ligand having biological activity |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EA013563B1 (en) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies |
| JP4340062B2 (en) | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | Concentrated protein preparation with reduced viscosity |
| JP2004526419A (en) | 2000-10-16 | 2004-09-02 | フィロス インク． | Protein scaffolds for antibody mimics and other binding proteins |
| CA2424371A1 (en) | 2000-10-20 | 2003-04-01 | Chugai Seiyaku Kabushiki Kaisha | Agonistic monoclonal antibody fragments |
| DE60143544D1 (en) | 2000-12-12 | 2011-01-05 | Medimmune Llc | MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE |
| EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
| UA83791C2 (en) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Antibody to vla-1, pharmaceutical composition, containing thereof, and use of them for treatment individual having immunological disorder, mediated by vla-1 |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| EP1780273B1 (en) | 2001-06-22 | 2010-10-06 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
| US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
| MXPA04003798A (en) | 2001-10-25 | 2004-07-30 | Genentech Inc | Glycoprotein compositions. |
| US20030190705A1 (en) | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
| DE10156482A1 (en) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispecific antibody molecule |
| CA2472922A1 (en) | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Antibody variants with faster antigen association rates |
| AU2003227504A1 (en) | 2002-04-15 | 2003-10-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF CONSTRUCTING scDb LIBRARY |
| DE60327199D1 (en) | 2002-04-26 | 2009-05-28 | Chugai Pharmaceutical Co Ltd | PROCESS FOR SCREENING AGONISTIC ANTIBODIES |
| EP1510943A4 (en) | 2002-05-31 | 2007-05-09 | Celestar Lexico Sciences Inc | Interaction predicting device |
| JP2004086862A (en) | 2002-05-31 | 2004-03-18 | Celestar Lexico-Sciences Inc | Apparatus, method and program for processing protein interaction information, and recording medium |
| US20060141456A1 (en) | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| CN100480260C (en) | 2002-07-18 | 2009-04-22 | 克鲁塞尔荷兰公司 | Recombinant production of mixtures of antibodies |
| EP1539947A4 (en) | 2002-08-15 | 2006-09-06 | Epitomics Inc | Humanized rabbit antibodies |
| AU2003269456A1 (en) | 2002-10-07 | 2004-04-23 | Mempile Inc. | Tight focusing method and system |
| GB0224082D0 (en) | 2002-10-16 | 2002-11-27 | Celltech R&D Ltd | Biological products |
| WO2004060919A1 (en) | 2002-12-26 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | Agonist antibody against heteroreceptor |
| WO2004065611A1 (en) | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of screening light chain of antibdoy |
| EP1608684A2 (en) | 2003-02-07 | 2005-12-28 | Protein Design Labs, Inc. | Amphiregulin antibodies and their use to treat cancer and psoriasis |
| GB2400851B (en) | 2003-04-25 | 2004-12-15 | Bioinvent Int Ab | Identifying binding of a polypeptide to a polypeptide target |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| EP2395016A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| ES2537738T3 (en) | 2003-06-05 | 2015-06-11 | Genentech, Inc. | Combination therapy for B cell disorders |
| US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| JP2005101105A (en) | 2003-09-22 | 2005-04-14 | Canon Inc | Positioning device, exposure apparatus, and device manufacturing method |
| WO2005035754A1 (en) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| SI2418220T1 (en) | 2003-12-10 | 2017-10-30 | E. R. Squibb & Sons, L.L.C. | Interferon alpha antibodies and their uses |
| WO2005058815A2 (en) | 2003-12-10 | 2005-06-30 | Medarex, Inc. | Ip-10 antibodies and their uses |
| WO2005062916A2 (en) | 2003-12-22 | 2005-07-14 | Centocor, Inc. | Methods for generating multimeric molecules |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| MX350383B (en) | 2004-01-09 | 2017-09-04 | Pfizer | ANTIBODIES TO MAdCAM. |
| CA2561264A1 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005112564A2 (en) | 2004-04-15 | 2005-12-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Germline and sequence variants of humanized antibodies and methods of making and using them |
| AR049390A1 (en) | 2004-06-09 | 2006-07-26 | Wyeth Corp | ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME |
| US20060019342A1 (en) | 2004-06-25 | 2006-01-26 | Medimmune, Inc. | Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis |
| SI2471813T1 (en) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimized Fc variants |
| EP1778728A2 (en) | 2004-08-19 | 2007-05-02 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| EP1799718A1 (en) | 2004-09-14 | 2007-06-27 | National Institute for Biological Standards and Control (NIBSC) | Vaccine |
| WO2006031994A2 (en) | 2004-09-14 | 2006-03-23 | Xencor, Inc. | Monomeric immunoglobulin fc domains |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| CA2586803C (en) | 2004-12-14 | 2012-12-11 | Ge Healthcare Bio-Sciences Ab | Purification of immunoglobulins |
| EP2208783A1 (en) | 2004-12-22 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
| EP1870458B1 (en) | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2 STRUCTURAL ISOMERS |
| WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| JP4917024B2 (en) * | 2005-04-08 | 2012-04-18 | 中外製薬株式会社 | Blood coagulation factor VIII functional substitute antibody |
| ES2446923T3 (en) | 2005-04-15 | 2014-03-10 | Genentech, Inc. | HGF beta chain variants |
| CA2607281C (en) | 2005-05-05 | 2023-10-03 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
| EP1908482B1 (en) | 2005-06-10 | 2017-09-06 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| EP1900814A4 (en) | 2005-06-10 | 2010-07-21 | Chugai Pharmaceutical Co Ltd | sc(Fv)2 SITE-DIRECTED MUTANT |
| EP1893647A2 (en) | 2005-06-23 | 2008-03-05 | MedImmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| AU2006270168B2 (en) | 2005-07-15 | 2012-05-03 | The University Of Vermont And State Agriculture College | Highly sensitive immunoassays and antibodies for detection of blood factor VIII |
| WO2007024535A2 (en) | 2005-08-19 | 2007-03-01 | Wyeth | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
| WO2007060411A1 (en) | 2005-11-24 | 2007-05-31 | Ucb Pharma S.A. | Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
| PL2047863T3 (en) | 2006-06-08 | 2014-01-31 | Chugai Pharmaceutical Co Ltd | Preventive or remedy for inflammatory disease |
| JP2009541275A (en) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | Production of bispecific antibodies |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| WO2008090960A1 (en) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2 |
| WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2666787B1 (en) | 2007-05-31 | 2022-02-09 | Genmab A/S | STABLE IgG4 ANTIBODIES |
| AU2007358045A1 (en) | 2007-08-23 | 2009-02-26 | Lfb Biotechnologies | Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the C1 domain of factor VIII |
| AU2008304756B8 (en) | 2007-09-26 | 2015-02-12 | Chugai Seiyaku Kabushiki Kaisha | Anti-IL-6 receptor antibody |
| SG10201605394SA (en) | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| TWI418363B (en) | 2007-09-28 | 2013-12-11 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody with improved plasma kinetics |
| PE20091174A1 (en) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT |
| ES2774337T3 (en) | 2008-01-07 | 2020-07-20 | Amgen Inc | Method for manufacturing heterodimeric Fc molecules of antibodies using electrostatic conduction effects |
| NZ623716A (en) | 2008-04-11 | 2016-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CA2722600C (en) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| EP2409990A4 (en) | 2009-03-19 | 2013-01-23 | Chugai Pharmaceutical Co Ltd | Antibody constant region variant |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| SG175077A1 (en) | 2009-04-07 | 2011-11-28 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| CN101906160A (en) | 2009-06-05 | 2010-12-08 | 苏州泽璟生物制药有限公司 | Human blood coagulation factor VIII resisting monoclonal antibody as well as preparation method and application thereof |
| KR102010827B1 (en) | 2009-06-26 | 2019-08-14 | 리제너론 파마슈티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2785414C (en) | 2009-12-25 | 2019-01-22 | Tomoyuki Igawa | Polypeptide modification method for purifying polypeptide multimers |
| TWI609698B (en) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody-containing solution preparation |
| JP5820800B2 (en) | 2010-03-02 | 2015-11-24 | 協和発酵キリン株式会社 | Modified antibody composition |
| PE20130393A1 (en) | 2010-03-11 | 2013-04-07 | Rinat Neuroscience Corp | ANTIBODIES WITH PH-DEPENDENT ANTIGEN UNION |
| US9162161B2 (en) | 2010-03-31 | 2015-10-20 | Jsr Corporation | Filler for affinity chromatography |
| KR102152109B1 (en) | 2010-04-20 | 2020-09-07 | 젠맵 에이/에스 | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| RU2624027C2 (en) | 2010-04-23 | 2017-06-30 | Дженентек, Инк. | Heteromultimeric proteins production |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| AU2010355558A1 (en) | 2010-06-14 | 2013-01-24 | Paion Deutschland Gmbh | Treatment of coagulopathy with hyperfibrinolysis |
| JP2013537416A (en) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | Monomer polypeptide containing mutant Fc region and method of use |
| PL2635607T3 (en) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| KR101962483B1 (en) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor VIII |
| KR102108521B1 (en) | 2011-03-25 | 2020-05-11 | 아이크노스 사이언스 에스. 아. | Hetero-dimeric Immunoglobulins |
| WO2013060867A2 (en) | 2011-10-27 | 2013-05-02 | Genmab A/S | Production of heterodimeric proteins |
| KR102168733B1 (en) | 2011-10-31 | 2020-10-23 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
| CN109897103B (en) | 2011-11-04 | 2024-05-17 | 酵活英属哥伦比亚有限公司 | Stable heterodimeric antibody design with mutations in the Fc domain |
| ES2816078T3 (en) | 2011-12-20 | 2021-03-31 | Medimmune Llc | Modified Polypeptides for Bispecific Antibody Scaffolds |
| GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| CA2860543C (en) | 2012-03-08 | 2018-04-24 | F. Hoffmann-La Roche Ag | Abeta antibody formulation |
| US9815909B2 (en) | 2012-03-13 | 2017-11-14 | Novimmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| NZ630551A (en) | 2012-04-20 | 2017-11-24 | Merus Nv | Methods and means for the production of ig-like molecules |
| WO2014028354A1 (en) | 2012-08-13 | 2014-02-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| PL2902787T3 (en) | 2012-09-28 | 2018-08-31 | Chugai Seiyaku Kabushiki Kaisha | Method for evaluating blood coagulation reaction |
| US9714291B2 (en) | 2012-10-05 | 2017-07-25 | Kyowa Hakko Kirin Co., Ltd | Heterodimer protein composition |
| CA2889951C (en) | 2012-11-02 | 2023-04-18 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
| UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
| MX2015006758A (en) | 2012-11-28 | 2016-06-10 | Zymeworks Inc | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof. |
| AU2014233528B2 (en) | 2013-03-15 | 2019-02-28 | Abbvie Biotherapeutics Inc. | Fc variants |
| BR112016006197B1 (en) | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY |
| CN110627907B (en) | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | Production of heterodimeric immunoglobulins that re-target T cells |
| UA117289C2 (en) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Multispecific antibodies |
| US11306156B2 (en) | 2014-05-28 | 2022-04-19 | Zymeworks Inc. | Modified antigen binding polypeptide constructs and uses thereof |
| TW201625299A (en) | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
| TWI700300B (en) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII) |
| TWI701435B (en) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | Method to determine the reactivity of FVIII |
| JP6630036B2 (en) | 2014-09-30 | 2020-01-15 | Jsr株式会社 | Method for purifying target substance and carrier for mixed mode |
| WO2016159213A1 (en) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | Method for producing polypeptide hetero-oligomer |
| JP2018123055A (en) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | Pharmaceutical composition for use in prevention and/or treatment of blood coagulation factor xi (fxi) abnormalities comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii (fviii) |
| JP6954842B2 (en) | 2015-12-25 | 2021-10-27 | 中外製薬株式会社 | Antibodies with enhanced activity and methods for modifying them |
| AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| TW202402326A (en) | 2016-04-28 | 2024-01-16 | 日商中外製藥股份有限公司 | Antibody-containing preparation |
| JP7301540B2 (en) | 2016-05-26 | 2023-07-03 | チールー ピュージェット サウンド バイオセラピューティクス コーポレイション | mixture of antibodies |
| CN117143247A (en) | 2016-07-19 | 2023-12-01 | 伊班绰斯有限责任公司 | Bispecific proteins and methods of making same |
| WO2018021450A1 (en) | 2016-07-29 | 2018-02-01 | 中外製薬株式会社 | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| IL265144B1 (en) | 2016-09-06 | 2024-06-01 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| PE20210005A1 (en) | 2017-09-29 | 2021-01-05 | Chugai Pharmaceutical Co Ltd | MULTISPECIFIC ANTIGEN BINDING MOLECULA THAT HAS SUBSTITUTE ACTIVITY OF THE COFACTOR FUNCTION OF BLOOD COAGULATION FACTOR VIII (FVIII) AND PHARMACEUTICAL FORMULATION THAT CONTAINS SUCH MOLECULA AS ACTIVE INGREDIENT |
-
2011
- 2011-11-17 KR KR1020137013908A patent/KR101962483B1/en active IP Right Grant
- 2011-11-17 PL PL11842145T patent/PL2644698T3/en unknown
- 2011-11-17 EP EP11842145.2A patent/EP2644698B1/en active Active
- 2011-11-17 SI SI201131447T patent/SI2644698T1/en unknown
- 2011-11-17 AU AU2011330184A patent/AU2011330184B2/en active Active
- 2011-11-17 CN CN201610299812.XA patent/CN105859889B/en active Active
- 2011-11-17 RU RU2013118448A patent/RU2620071C2/en active
- 2011-11-17 KR KR1020137018781A patent/KR101398363B1/en active Protection Beyond IP Right Term
- 2011-11-17 KR KR1020137018788A patent/KR101398290B1/en active IP Right Grant
- 2011-11-17 ES ES11842145.2T patent/ES2660151T3/en active Active
- 2011-11-17 BR BR112013012213-7A patent/BR112013012213A2/en not_active Application Discontinuation
- 2011-11-17 MY MYPI2013700794A patent/MY166429A/en unknown
- 2011-11-17 KR KR1020197007879A patent/KR102099580B1/en active IP Right Grant
- 2011-11-17 LT LTEP11842145.2T patent/LT2644698T/en unknown
- 2011-11-17 CA CA2817964A patent/CA2817964C/en active Active
- 2011-11-17 TW TW100141973A patent/TWI629355B/en active
- 2011-11-17 HU HUE11842145A patent/HUE038305T2/en unknown
- 2011-11-17 PH PH12016502073A patent/PH12016502073A1/en unknown
- 2011-11-17 TW TW102146541A patent/TWI452136B/en active
- 2011-11-17 RS RS20180318A patent/RS57038B1/en unknown
- 2011-11-17 EP EP17200495.4A patent/EP3318633A1/en active Pending
- 2011-11-17 WO PCT/JP2011/076486 patent/WO2012067176A1/en active Application Filing
- 2011-11-17 NO NO11842145A patent/NO2644698T3/no unknown
- 2011-11-17 DK DK11842145.2T patent/DK2644698T3/en active
- 2011-11-17 PT PT118421452T patent/PT2644698T/en unknown
- 2011-11-17 US US13/885,421 patent/US9334331B2/en active Active
- 2011-11-17 JP JP2012544291A patent/JP6013915B2/en active Active
- 2011-11-17 CN CN201180065133.1A patent/CN103298937B/en active Active
- 2011-11-17 TR TR2018/02772T patent/TR201802772T4/en unknown
- 2011-11-17 TW TW105115923A patent/TW201631153A/en unknown
- 2011-11-17 MX MX2013005394A patent/MX355060B/en active IP Right Grant
- 2011-11-17 TW TW102146540A patent/TWI452135B/en active
-
2013
- 2013-02-01 JP JP2013018259A patent/JP5246906B1/en active Active
- 2013-02-01 JP JP2013018255A patent/JP5246905B1/en active Active
- 2013-07-04 RU RU2013130595/10A patent/RU2534347C1/en active
- 2013-07-04 RU RU2013130596A patent/RU2534564C3/en active Protection Beyond IP Right Term
- 2013-09-05 US US14/019,117 patent/US20140370018A1/en not_active Abandoned
- 2013-09-06 US US14/019,712 patent/US20140037632A1/en not_active Abandoned
-
2016
- 2016-04-19 US US15/132,996 patent/US10450381B2/en active Active
- 2016-05-30 AU AU2016203564A patent/AU2016203564B2/en active Active
- 2016-09-23 JP JP2016185421A patent/JP6710131B2/en active Active
- 2016-10-05 HK HK16111570.7A patent/HK1223379A1/en unknown
- 2016-10-07 US US15/288,965 patent/US20170022293A1/en not_active Abandoned
-
2018
- 2018-03-09 HR HRP20180421TT patent/HRP20180421T1/en unknown
- 2018-05-30 LU LU00076C patent/LUC00076I2/en unknown
- 2018-05-30 NL NL300940C patent/NL300940I2/en unknown
- 2018-06-13 LT LTPA2018507C patent/LTC2644698I2/en unknown
- 2018-06-21 HU HUS1800029C patent/HUS1800029I1/en unknown
- 2018-07-19 FR FR18C1031C patent/FR18C1031I2/en active Active
-
2019
- 2019-03-05 JP JP2019039114A patent/JP6823677B2/en active Active
- 2019-07-02 US US16/459,791 patent/US20190315884A1/en not_active Abandoned
-
2021
- 2021-01-08 JP JP2021002057A patent/JP2021065233A/en active Pending
-
2022
- 2022-04-26 US US17/729,471 patent/US20220267470A1/en not_active Abandoned
- 2022-10-12 JP JP2022163711A patent/JP2022191374A/en active Pending
- 2022-12-15 US US18/081,874 patent/US20230212315A1/en not_active Abandoned
-
2023
- 2023-09-06 NO NO2023034C patent/NO2023034I1/en unknown
- 2023-10-27 US US18/495,861 patent/US20240059795A1/en not_active Abandoned